Full-Time

Senior Manager Forecasting-Neuropsych

Biogen

Biogen

5,001-10,000 employees

Develops therapies for neurological disorders

Compensation Overview

$142k - $190k/yr

+ Bonus + Equity Incentive

Cambridge, MA, USA

In Person

Category
Finance & Banking (1)
Required Skills
Market Research
Forecasting
Data Analysis
Excel/Numbers/Sheets
Requirements
  • BA/BS required (Preferred in Mathematics, Statistics, Economics or Health Economics and Outcomes Research)
  • 5-7 years strategic consulting experience in Pharma / Biotech / Medical Device industry or relevant experience, level to be assessed based on relevant experience
  • Prior experience in a strategic forecasting role. Minimum 1-3 years in Forecasting for Senior Manager. Depth of knowledge in 1-2 Therapeutic Areas is preferred
  • Foundational knowledge and understanding of key data sets and processes like Sales conversion cycles, knowledge of wholesaler/SP/PSS data and KPIs and how to use them for modelling sales/demand and inventory modelling, knowledge of how to interpret and use Demand studies from Market research, knowledge of how to use software like Crystal Ball/ at risk to run Monte- Carlo simulations and other statistical analysis to predict risk and opportunities in forecast. Knowledge of how to assess an Epidemiology-based Model and how to interpret and select Real-World Evidence studies for forecast Modelling.
  • High Analytical Horsepower / Skillset – Very strong analytical and quantitative skill set, including Excel modeling skills; high comfort sourcing, manipulating, analyzing using Excel and other modeling tools, and visualizing data via standard tools/charting methods; ability to effectively present and defend analyses
  • Strong Project / Deliverable Management – Ability to deliver complex analytical investigations and cross-functional projects with limited guidance; ability to scope, enhance the output/hypotheses and deliver analytical investigations and projects with limited oversight; seeks to understand the problem/issue, conducts cross-functional interviews and drives towards a well-structured deliverable
  • Strategic Thinking – Strong business acumen & communication skills and ability to work with and present to leadership. Great strategic problem-solving skills, leading structured thinking around complex problems to enable data-driven decision-making. Able to independently design/identify the ideal approach to answering complex business questions pulling from all available internal/external data sources; able to draft synthesized outputs and drive beyond the raw output of the analysis to actionable insights; anticipates the next question(s) from management
  • Cross-Functional Collaboration – Able to collaborate effectively with various functional partners to probe/ask questions, gather required information for analysis and participate as a value-added cross-functional partner
Responsibilities
  • Own and drive the short- and long-term Brand/Market Revenue planning, including presenting recommendations to key brand stakeholders (Marketing, I&A leads, Finance) proactively and reactively developing business case scenarios, and ensuring alignment on core assumptions based on insights.
  • Utilize advanced statistical methods and forecasting and develop models using Epidemiology funnel, Monthly/weekly actual sales/demand, inventory and Revenue deductions dynamics to Forecast short term and Long term Sales forecasts.
  • Conduct ad hoc scenario planning exercises (Monte Carlo, Latin Hypercube sampling, Risk and Opps) to anticipate and model potential changes in market conditions, impact of business decisions, and develop strategies to address various scenarios.
  • Partner with Market Research team to design and interpret conjoint and demand estimation studies. Partner with Analytics team to leverage claim based KPIs in building forecast Model. Partner with Market Access teams to understand impact of Revenue deductions on Long term and Short term forecast and build variables in Model. Partner with Finance teams to drive short term and long term Revenue goals for the Brand and Franchise.
  • Collaborate with Brand, Customer Data and Insights, Finance, and Global Strategic Forecasting teams on long range planning exercises for the US.
  • In partnership with the investor relations team, reconcile external (e.g. Wall Street) forecast models and assumptions with internal views.
  • Assess and implement advanced forecasting technologies and tools to improve the precision and timeliness of predictions.
  • Lead the Forecasting model creation, maintenance, and evolution
  • Act as a Project Leader or Project Manager in TA critical projects.
  • Foster experience exchange and learning loops through internal community engagement, creating opportunities to nurture and support new ideas and showcase best practices and market trends.
  • Drive a process and create documentation for respective brand/franchise that effectively uses all available and relevant data and insights to indicate if forecast achievement is on track. This includes using and understanding claims based, Market research calculated KPI’s to drive the assessment.

Biogen is a global biotechnology company focused on neuroscience. It discovers, develops, and delivers therapies for neurological disorders, such as multiple sclerosis and other neurodegenerative diseases. Its product process starts with research and development to identify potential drugs, followed by clinical testing and regulatory approval, ultimately leading to commercialization and patient treatment. Biogen differentiates itself through a long history (founded in 1978), a deep specialization in neuroscience, and an integrated pipeline that moves ideas from discovery to approved medicines, aiming to create value for shareholders while helping communities. The company’s goal is to advance therapies for neurological diseases to improve patients’ lives and generate sustainable value for stakeholders.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

1978

Simplify Jobs

Simplify's Take

What believers are saying

  • Leqembi sales surged 74% to $168 million in Q1 2026, driving Alzheimer's growth.
  • Non-MS products generate 45% of revenue, diversifying beyond multiple sclerosis franchise.
  • Felzartamab Phase 3 readout in 2027 validates $5.6 billion Apellis and HI-Bio investments.

What critics are saying

  • Multiple sclerosis sales stagnate at $957.5 million in Q1 2026 from Novartis Kesimpta competition.
  • Spinraza revenue drops 12% to $374 million in Q1 2026 due to generic erosion.
  • $5.6 billion Apellis deal incurs $1 per share charges, cutting 2026 EPS to $14.25-$15.25.

What makes Biogen unique

  • Apellis acquisition adds Empaveli and Syfovre for immunology and rare kidney diseases.
  • Felzartamab targets CD38 in Phase 3 trials for IgA nephropathy and membranous nephropathy.
  • Alloy's AntiClastic ASO platform enhances antisense drug potency for undisclosed indications.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Biogen who can refer or advise you

Benefits

Remote Work Options

Professional Development Budget

Company News

Pharma Focus Asia
Apr 21st, 2026
Biogen Inc. to invest in felzartamab rights in Greater China through agreement with TJ Biopharma.

Biogen Inc. to invest in felzartamab rights in Greater China through agreement with TJ Biopharma. Tuesday, April 21, 2026 Biogen Inc. has entered into a definitive agreement to invest in the exclusive rights to felzartamab held by TJ Biopharma in the Greater China region. Following the agreement, Biogen will hold exclusive global rights to the drug candidate, which is currently under Phase 3 clinical evaluation for several immune-mediated diseases. Under the terms of the deal, TJ Biopharma will receive an upfront payment of $100 million. The company is also eligible for up to $750 million in milestone payments linked to commercial and sales performance, taking the total potential value of the agreement to $850 million. In addition, TJ Bio will earn royalties in the mid-single-digit to low-double-digit percentage range on net sales in the Greater China region. Biogen plans to record the upfront payment as an acquired in-process research and development expense in the second quarter of 2026. As part of the transaction, Biogen will also take over milestone and royalty obligations tied to an earlier licensing agreement with MorphoSys, a subsidiary of Novartis. Biogen had earlier secured global rights to felzartamab, excluding Greater China, through its acquisition of HI-Bio in July 2024. The company has since initiated Phase 3 trials targeting conditions such as antibody-mediated rejection in kidney transplant patients, IgA nephropathy, and primary membranous nephropathy, with plans to expand into additional indications. The agreement builds on ongoing collaboration between the two companies. In April 2025, TJ Bio joined two global Phase 3 trials sponsored by Biogen, focusing on IgA nephropathy and primary membranous nephropathy in China. Both conditions are major contributors to kidney disease in the country, with a large patient population affected. Biogen will continue to lead clinical development in immunology, and will also take responsibility for manufacturing and commercial activities for felzartamab in the Greater China region. A biologics licence application for felzartamab, submitted by TJ Bio in December 2024 for the treatment of multiple myeloma, is currently under review by the National Medical Products Administration. Following approval, Biogen will oversee post-approval activities in the region, while TJ Bio will act as the manufacturing partner for this indication at its Hangzhou GMP plant.

Genetic Engineering and Biotechnology News
Apr 10th, 2026
Drugs from a text prompt, Wegovy pill competition dampens Lilly's surge.

Drugs from a text prompt, Wegovy pill competition dampens Lilly's surge. April 10, 2026 From designing drugs with a simple text prompt to running experiments guided by extended reality, a new wave of agentic AI is transforming the modern lab. Its editors discuss the latest autonomous systems accelerating biological discovery. In business deals, Gilead Sciences has acquired Tubulis in a transaction worth up to $5 billion, strengthening the buyer's position in antibody-drug conjugates for cancer. Correspondingly, Eli Lilly and Biogen are each making billion-dollar-plus bets, acquiring Centessa, a sleep disorder drug developer, and Apellis, known for its work in immunology and rare diseases. Its episode rounds out by unpacking the dynamic obesity drug market, where intensifying competition from Novo Nordisk's Wegovy pill is prompting Lilly to temper the 2026 sales outlook for its oral obesity drug, Foundayo. Listed below are links to the GEN stories referenced in this episode of Touching Base:

Benzinga
Apr 7th, 2026
Biogen taps Alloy platform to push antisense drug pipeline forward.

Biogen taps Alloy platform to push antisense drug pipeline forward. Stock score locked: want to see it? Benzinga Rankings give you vital metrics on any stock - anytime. Biogen Inc. (NASDAQ:BIIB) on Tuesday entered into an agreement with Alloy Therapeutics Inc. to accelerate the development of antisense therapies targeting multiple undisclosed indications. Waltham, Massachusetts-based Alloy will receive an upfront payment and stands to earn additional milestone-based compensation, along with tiered royalties on any commercialized products arising from the partnership. Expanding rna-targeted drug development. Alloy's AntiClastic ASO platform is designed to improve the effectiveness of antisense therapeutics by enabling drug developers to target disease pathways at the RNA level within cells. The approach seeks to address longstanding challenges in the field, particularly around drug potency and therapeutic index. Historically, antisense drugs have faced limitations due to poor biodistribution, which has constrained their clinical efficacy. Alloy's broader technology ecosystem. Alloy Therapeutics operates a diversified platform model aimed at accelerating drug discovery. Its ecosystem integrates multiple technologies, including computational and AI-driven tools, to enhance therapeutic development and optimization. The collaboration with Biogen reflects continued interest in leveraging advanced platforms to improve drug discovery efficiency and expand the potential of RNA-based therapeutics. In January 2025, Alloy Therapeutics inked a target-specific collaboration and license agreement for the use of their novel and proprietary AntiClastic Antisense Platform with Sanofi SA (NASDAQ:SNY) for a central nervous system (CNS) target. In return, Sanofi paid an upfront license fee and near-term preclinical milestone payments up to $27.5 million. Alloy is also eligible to receive discovery, development, and commercial milestone payments of over $400 million. Biogen expands portfolio with Apellis deal. Last week, Biogen agreed to acquire Apellis Pharmaceuticals Inc. (NASDAQ:APLS) for $41 per share in cash or approximately $5.6 billion. The acquisition is expected to enhance Biogen's growth portfolio in immunology and rare diseases. The deal consideration includes a contingent value right (CVR) for each share. It allows shareholders to receive two payments of $2 per share based on certain sales thresholds for Apellis. BIIB Stock Price Activity: Biogen shares closed at $172.34 on Monday, according to Benzinga Pro data. Everyone Bought NVIDIA. The Smart Money Is Now Buying What NVIDIA Needs to Run. The chip trade is crowded. Valuations are stretched. The investors who made money on Phase 1 of AI are already repositioning into the one thing every data center depends on: uninterrupted power. Natural gas and nuclear are the only sources that can deliver it at scale - and one small company just landed a deal to power multiple new hyperscale data centers. Posted In: Discover Private Market Opportunities Join 385,000+ Investors

Business Wire
Apr 7th, 2026
Biogen licenses Alloy's AntiClastic™ ASO platform for multi-target antisense drug development

Alloy Therapeutics has entered a collaboration and licence agreement with Biogen for use of its AntiClastic ASO Platform to develop antisense therapeutics against multiple undisclosed targets. Alloy will receive an upfront payment and is eligible for milestone payments and tiered royalties on resulting products. The AntiClastic ASO platform addresses potency and therapeutic index challenges that have historically limited antisense drugs due to biodistribution constraints. The technology combines improvements in primary sequence with proprietary spatial conformation of nucleic acids to enhance delivery to target RNA whilst mitigating inflammatory responses. Alloy Therapeutics is a biotechnology ecosystem company that provides access to AI-powered drug discovery platforms and scientific expertise across multiple therapeutic modalities, including antibodies, bispecifics, genetic medicines and cell therapies.

Yahoo Finance
Apr 3rd, 2026
GoDaddy and Biogen struggle despite cash flow, Champion Homes surges with 29.4% EPS growth

Biogen, a pioneer in neurological treatments, faces significant headwinds despite its 20.7% free cash flow margin. The company's sales have declined 6% annually over the past five years, with earnings per share falling 14.2% annually during the same period. Founded in 1978, Biogen develops therapies for multiple sclerosis, Alzheimer's disease, spinal muscular atrophy and rare diseases. However, its products face end-market challenges, and diminishing returns on capital suggest earlier profit pools are drying up. Trading at $177.40 per share, or 11.6x forward price-to-earnings, Biogen illustrates that strong cash flow alone doesn't guarantee superior returns when underlying business fundamentals weaken.